Well here it is, Dec 1, and I don't think the Covid trial has started dosing. Also the Sheikh has long ago rode off into the sunset and the ship full of gold from Africa has not yet arrived. Nothing has been achieved on the business side since the announcement of the BoM top line data on Sept 30, 2019 and probably long before then.

I also would like to echo the thoughts of others and thank the science and medical posters for their insights into RVX's science because without these posters I would know nothing about apabetalone and it's potential to help improve quality of life for thousands of people with many serious afflictions.

My Christmas wish list is short.

1. I would like to see a forum held in which an open discussion and question and answer session is held discussing BETi inhibition and the strengths, weaknesses and potential for apabetalone. This discussion would involve scientists at RVX including Drs Kulikowski, Sweeney, Wong, Johansson, Jahagirdar and others involved in the cardio and kidney research. It would also include an independent panel of other BETi experts. The goal would be to establish the current state of thinking on what is known, what needs to be known and future direction. It would be an open and honest exchange of ideas.
2. My second wish is for the BOD and RVX to appoint a new CEO to RVX. This person would be highly respected and trusted in the biotech sphere as well as the biotech investment field. IMHO such a move would immediately move our share price to the $5 range. It would also rebrand RVX as a biotech to respect.

I know I am dreaming but that is what Christmas is about. An open and honest discussion required.

I can't imaging how low Don's reputation must be in the North American biotech financial community for RVX to be in this awful state of affairs.

GLTA

Toinv